Phobic Disorders Clinical Trial
Official title:
A Randomized Controlled Study of the Effect of a Needle Phobia or Apprehension Intervention With or Without Synera® on Conversion From Central Venous Catheters to Arteriovenous Fistula or Graft
An arteriovenous fistula or graft access (AVF/AVG) for dialysis is often considered a superior option for delivery of dialysis, but requires needles to be inserted. Patients on dialysis who indicate fear of needles as the reason for not switching from a long-term central venous catheter (CVC) access to a fistula or graft access and who otherwise meet the eligibility criterial will be asked to participate. Patients will receive either a standard or an enhanced intervention to address their fear of needles. The enhanced intervention includes the standard intervention plus video training about Synera and trying out an actual patch. Over the 4 months following the intervention, how many patients sign up to switch access will be tracked.
Patients with long-term CVCs (> 180 days) will be recruited for study participation by being
asked "Why haven't you gotten a graft or fistula?" Those who indicate fear or discomfort
with needles in the top 3 reasons will be consented into the study and administered the
AVF/AVG Stages of Change Questionnaire.
The Stages of Change questionnaire has been used extensively in research and has been shown
to be highly predictive of people engaging in the behavior of interest. The five stages of
change include: 1) Precontemplation: Patient doesn't know about, or knows about but doesn't
want to think about, a behavior change; 2) Contemplation: Patients knows about and is
beginning to consider behavior change; 3) Planning: Patient is actively investigating and
making plans for behavior change; 4) Action: Patient is committed to make the change and/or
has taken concrete steps to change behavior; and 5) Maintenance: Patient has made the
behavior change and is trying maintain that change.
Patients will be cluster-randomized to receive a standard needle phobia intervention (n =
32), or an enhanced intervention consisting of a standard intervention plus a demonstration
of the Synera patch (n = 32) within 15 days of baseline. The intervention will be
administered by a study team member. In clinics where there is more than 1 patient
randomized to a group, the intervention can be administered to multiple patients
simultaneously. The standard intervention will last approximately 20 to 30 minutes. During
this time, patients will receive information about the advantages of arteriovenous fistula
or graft over central-venous catheter, be taught basic relaxation breathing, see a brief
video of a patient overcoming needle fear, and have the opportunity to safely interact with
a cannulation needle. In the enhanced intervention, the patient will receive the standard
intervention with 2 enhancements: (1) the video will include a segment in which a patient
experiences the analgesic effects of the a Synera patch and (2) a Synera patch will be
applied at the beginning of the intervention, and 30 minutes later the patient will be given
the chance to explore the analgesic effects of Synera.
Patients will complete a Stages of Change questionnaire 1 week after the intervention.
Patients will then be followed for 4 months to determine whether or not they have scheduled
a vein mapping appointment or have had a fistula or graft access placed.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01963806 -
ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder
|
N/A | |
Completed |
NCT00121069 -
Study of Escitalopram in the Treatment of Specific Phobia
|
Phase 2/Phase 3 | |
Recruiting |
NCT03653923 -
Neurophysiological Correlates of Exposition Therapy in Spider Phobia
|
N/A | |
Completed |
NCT00184106 -
RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo
|
Phase 4 | |
Completed |
NCT00051220 -
Treatment for Specific Phobias in Children
|
Phase 1/Phase 2 | |
Completed |
NCT02310152 -
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
|
N/A | |
Completed |
NCT02387047 -
Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly
|
N/A | |
Completed |
NCT00000370 -
Treatment of Social Phobia
|
N/A | |
Completed |
NCT03012035 -
The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants
|
N/A | |
Completed |
NCT02007694 -
Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03188575 -
Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT
|
N/A | |
Completed |
NCT02432703 -
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
|
Phase 2 | |
Terminated |
NCT01574014 -
Glucocorticoid Treatment for Social Phobia
|
Phase 2 | |
Completed |
NCT00734422 -
Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02336802 -
Threat-Avoidance Learning in Anxiety Patients
|
N/A | |
Completed |
NCT01361074 -
In Vivo Versus Augmented Reality Exposure for Small Animal Phobia
|
N/A | |
Completed |
NCT00104195 -
A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions
|
Phase 1 | |
Completed |
NCT00035412 -
St. John's Wort Versus Placebo in Social Phobia
|
Phase 2 | |
Completed |
NCT00128401 -
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
|
Phase 2 | |
Recruiting |
NCT02020824 -
Virtual Reality and Concept of Control in the Treatment of Acrophobia
|
N/A |